A three m6A-related regulators signature (FTO, RBM15, ALKBH5) could be used to effectively predict the clinicopathological features of GC patients (48), and a nine m6A-related lncRNA risk signature is an independent prognostic indicator for patients with GC, which can effectively predict survival status (49). This evidence concerns the gene ALKBH5 and gastric cancer.